Friday, October 12, 2018 2:31:19 AM
d-
Let's assume I am right and pps will be $25-30 before Nov 10 (for simplicity $28).
"approximately 25% relative risk reduction" is 27%: $30
Assuming that the endpoint is statistically significant, the pps on Nov 12:
- Key secondary endpoint: Composite of CV death, nonfatal MI, or nonfatal stroke: $33
Additional individual or composite endpoints (tested in order listed):
- Composite of CV death or nonfatal MI: $37
- Fatal or nonfatal MI: $40
- Nonelective coronary revascularization (defined as emergent or urgent): $42
- CV death: $50
- UA determined to be caused by myocardial ischemia by invasive/noninvasive testing and requiring emergent hospitalization: $52
- Fatal or nonfatal stroke: $55
- Total mortality: $60
[Please note: these are for Nov 12 only]
The PE RRR could be 23-24% and none of the SEs is ss (robust does not mean ss) … but I think: it isn't likely.
- - - - - The options and RSUs are (mostly) time dependent (some of them based on "event") will be vested in (e.g.) 2022 … OR … fully vested in case change of Control … but the offer itself does not mean a change of control (till it will be accepted / finalized).
Best,
G
Let's assume I am right and pps will be $25-30 before Nov 10 (for simplicity $28).
"approximately 25% relative risk reduction" is 27%: $30
Assuming that the endpoint is statistically significant, the pps on Nov 12:
- Key secondary endpoint: Composite of CV death, nonfatal MI, or nonfatal stroke: $33
Additional individual or composite endpoints (tested in order listed):
- Composite of CV death or nonfatal MI: $37
- Fatal or nonfatal MI: $40
- Nonelective coronary revascularization (defined as emergent or urgent): $42
- CV death: $50
- UA determined to be caused by myocardial ischemia by invasive/noninvasive testing and requiring emergent hospitalization: $52
- Fatal or nonfatal stroke: $55
- Total mortality: $60
[Please note: these are for Nov 12 only]
The PE RRR could be 23-24% and none of the SEs is ss (robust does not mean ss) … but I think: it isn't likely.
- - - - -
what options are you talking about? insider options should be counted at the time of an offer made, right?
Best,
G
"There are some things money can't buy. For everything else, there's AMRN."
Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
